The pharmaceutical industry is frequently characterized by its volatility and the complexities surrounding financial performance and regulatory compliance. A recent class action lawsuit filed against Biohaven Ltd. highlights the potential risks faced by companies in this sector as they attempt to navigate the delicate balance between innovation, market expectations, and financial accountability.
On September 6, 2025, the Pomerantz Law Firm announced a class action lawsuit against Biohaven Ltd. and certain officers, lodged in the United States District Court for the District of Connecticut. The lawsuit
Comments